This study aims to compare the outcomes of radical radiotherapy versus prostate radiotherapy alone in patients with de novo low-burden metastatic hormone-sensitive prostate cancer.
Reviewed patients with de novo low-burden metastatic hormone-sensitive prostate cancer receiving radical radiotherapy (Arm A) or prostate radiotherapy alone (Arm B).
Analyzed progression-free survival, overall survival, and treatment-related toxicity using Kaplan-Meier and Cox-proportional hazards models.
Included 127 eligible patients from a Hong Kong tertiary hospital between January 2012 and January 2023.
5-year progression-free survival was significantly better in Arm A (86.1%) compared to Arm B (50.3%), P=0.0173, HR 0.213, 95% CI 0.059-0.761.
Median follow-up was 40.2 months in Arm A and 30.3 months in Arm B.
No differences in treatment-related toxicities between the two treatment arms.